ArticleDiscover oncology2025
Analysis of the differences in immune indexes of common gene mutations and 5q- chromosome karyotype mutations in MDS.
Article in Discover oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- The role of macrophages and cytokines in the occurrence and development of MDS.Clinical and experimental medicine · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
objectiveThis study aims to investigate the interaction between common gene and 5q- chromosome karyotype mutations and the immune microenvironment in myelodysplastic syndromes (MDS), and explore the potential prognostic value of immune markers in MDS.
methodsA total of 83 MDS patients treated at the Second Hospital of Lanzhou University between January 2019 and April 2024 were enrolled in this study. Patients were divided into mutation and wild-type groups based on gene mutations and the presence of 5q- chromosomal abnormalities. Co-mutations in MDS patients were analyzed. A total of 19 fine immune parameters were measured in the samples using flow cytometry and flow cytometric bead array (CBA) technology. Changes in immune markers between the mutation and wild-type groups were observed, and the correlation between lymphocyte subsets and cytokines in the mutation group was analyzed.
resultsSignificant differences in immune markers were observed between the common gene mutation group and the wild-type group in MDS (P < 0.05). Correlations between lymphocyte subsets and cytokines were identified in ASXL1, RUNX1, SF3B1, TET2, TP53, U2AF1, and 5q- mutation groups.
conclusionThis study investigates the correlation between common MDS mutations and cytokine/lymphocyte subpopulations, preliminarily revealing the interaction between genetic factors and immune markers in myelodysplastic syndrome (MDS), and emphasizes the potential important role of the Th17/Treg axis in the tumor immune microenvironment of MDS, but does not verify the mechanism. The study suggests that fine immune parameters have potential prognostic value in MDS and may guide future MDS treatment strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.